TD Cowen downgrades Sarepta Therapeutics to Hold, reduces price target due to safety concerns

From Yahoo Finance: 2025-06-25 13:01:00

TD Cowen downgraded Sarepta Therapeutics (SRPT) stock to “Hold,” reducing the price target to $24 from $62 due to concerns over Elevidys FDA approval withdrawal. Safety issues led to a 30% liver function test elevation rate, prompting a re-evaluation of the treatment’s safety profile. Despite challenges in the biotech market, SRPT remains well-positioned with significant revenue and a deep pipeline. The company continues to proactively address safety concerns. While SRPT shows growth potential, other AI stocks may offer higher returns with less risk. For more insights on AI stocks, check out the report on the cheapest AI stock with significant upside potential.



Read more at Yahoo Finance: TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT